secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2026-08-13T21:21:36+00:00
Accession:  0001829126-26-008773
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc discusses NEO100-01 Phase 2a results; no data in filing excerpt
---------------------------------------------------------------------

- Hosted investor call on Aug 12, 2026 to discuss Phase 2a top-line results of NEO100-01 in recurrent IDH1 mutant high-grade glioma.
- Participants included CEO Amir Heshmatpour, CFO Keithly Garnett, CSO Thomas Chen, and Chief Clinical Officer Josh Neman.
- Provided transcript does not include specific efficacy or safety data; only call introduction is in the exhibit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626008773/0001829126-26-008773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626008773/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-008773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer